Market Overview

Report: Developing Opportunities within Clearwater Paper, Intercept Pharmaceuticals, Community Trust, Community Bank System, Laboratory Corporation of America, and Dicerna Pharmaceuticals — Future Expectations, Projections Moving into 2018

Share:

NEW YORK, July 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clearwater Paper Corporation (NYSE:CLW), Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), Community Trust Bancorp, Inc. (NASDAQ:CTBI), Community Bank System, Inc. (NYSE:CBU), Laboratory Corporation of America Holdings (NYSE:LH), and Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

CLW DOWNLOAD: http://Fundamental-Markets.com/register/?so=CLW
ICPT DOWNLOAD: http://Fundamental-Markets.com/register/?so=ICPT
CTBI DOWNLOAD: http://Fundamental-Markets.com/register/?so=CTBI
CBU DOWNLOAD: http://Fundamental-Markets.com/register/?so=CBU
LH DOWNLOAD: http://Fundamental-Markets.com/register/?so=LH
DRNA DOWNLOAD: http://Fundamental-Markets.com/register/?so=DRNA

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Clearwater Paper Corporation (NYSE:CLW), Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), Community Trust Bancorp, Inc. (NASDAQ:CTBI), Community Bank System, Inc. (NYSE:CBU), Laboratory Corporation of America Holdings (NYSE:LH), and Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed July 23rd, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

CLEARWATER PAPER CORPORATION (CLW) REPORT OVERVIEW

Clearwater Paper's Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Clearwater Paper reported revenue of $436.95MM vs $437.53MM (down 0.13%) and basic earnings per share $0.16 vs $0.46 (down 65.22%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Clearwater Paper reported revenue of $1,730.41MM vs $1,734.76MM (down 0.25%) and basic earnings per share $5.91 vs $2.91 (up 103.09%). Clearwater Paper is expected to report earnings on August 1st, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was $0.54. The estimated EPS forecast for the next fiscal year is $1.35 and is expected to report on February 4th, 2019.

To read the full Clearwater Paper Corporation (CLW) report, download it here: http://Fundamental-Markets.com/register/?so=CLW

-----------------------------------------

INTERCEPT PHARMACEUTICALS, INC. (ICPT) REPORT OVERVIEW

Intercept Pharmaceuticals' Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Intercept Pharmaceuticals reported revenue of $35.96MM vs $21.05MM (up 70.86%) and basic earnings per share -$3.22 vs -$3.61. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Intercept Pharmaceuticals reported revenue of $130.96MM vs $24.95MM (up 424.85%) and basic earnings per share -$14.38 vs -$16.74. Intercept Pharmaceuticals is expected to report earnings on July 30th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was -$3.46. The estimated EPS forecast for the next fiscal year is -$7.79 and is expected to report on February 13th, 2019.

To read the full Intercept Pharmaceuticals, Inc. (ICPT) report, download it here: http://Fundamental-Markets.com/register/?so=ICPT

-----------------------------------------

COMMUNITY TRUST BANCORP, INC. (CTBI) REPORT OVERVIEW

Community Trust's Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Community Trust reported interest income of $40.58MM vs $36.77MM (up 10.37%) and basic earnings per share $0.89 vs $0.64 (up 39.06%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Community Trust reported interest income of $155.70MM vs $146.58MM (up 6.22%) and basic earnings per share $2.92 vs $2.70 (up 8.15%). Community Trust is expected to report earnings on October 17th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.78. The estimated EPS forecast for the next fiscal year is $3.44 and is expected to report on January 16th, 2019.

To read the full Community Trust Bancorp, Inc. (CTBI) report, download it here: http://Fundamental-Markets.com/register/?so=CTBI

-----------------------------------------

COMMUNITY BANK SYSTEM, INC. (CBU) REPORT OVERVIEW

Community Bank System's Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Community Bank System reported interest income of $88.40MM vs $69.96MM (up 26.37%) and basic earnings per share $0.78 vs $0.58 (up 34.48%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Community Bank System reported interest income of $329.46MM vs $285.19MM (up 15.52%) and basic earnings per share $3.07 vs $2.34 (up 31.20%). Community Bank System is expected to report earnings on October 22nd, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.73. The estimated EPS forecast for the next fiscal year is $3.18 and is expected to report on January 28th, 2019.

To read the full Community Bank System, Inc. (CBU) report, download it here: http://Fundamental-Markets.com/register/?so=CBU

-----------------------------------------

LABORATORY CORPORATION OF AMERICA HOLDINGS (LH) REPORT OVERVIEW

Laboratory Corporation of America's Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Laboratory Corporation of America reported revenue of $2,848.30MM vs $2,413.70MM (up 18.01%) and basic earnings per share $1.70 vs $1.79 (down 5.03%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Laboratory Corporation of America reported revenue of $10,441.40MM vs $9,641.80MM (up 8.29%) and basic earnings per share $12.39 vs $7.14 (up 73.53%). Laboratory Corporation of America is expected to report earnings on July 25th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was $2.47. The estimated EPS forecast for the next fiscal year is $12.29 and is expected to report on February 5th, 2019.

To read the full Laboratory Corporation of America Holdings (LH) report, download it here: http://Fundamental-Markets.com/register/?so=LH

-----------------------------------------

DICERNA PHARMACEUTICALS, INC. (DRNA) REPORT OVERVIEW

Dicerna Pharmaceuticals' Recent Financial Performance

For the twelve months ended December 31st, 2017 vs December 31st, 2016, Dicerna Pharmaceuticals reported revenue of $2.28MM vs $0.30MM (up 671.86%) and basic earnings per share -$3.66 vs -$2.87. Dicerna Pharmaceuticals is expected to report earnings on August 9th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was -$1.15. The estimated EPS forecast for the next fiscal year is -$1.25 and is expected to report on March 14th, 2019.

To read the full Dicerna Pharmaceuticals, Inc. (DRNA) report, download it here: http://Fundamental-Markets.com/register/?so=DRNA

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Primary Logo

View Comments and Join the Discussion!